We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-9.1%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$377M
AUM Growth
-$101M
Cap. Flow
-$18.7M
Cap. Flow %
-4.96%
Top 10 Hldgs %
50.73%
Holding
91
New
7
Increased
20
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$5.15M
2
ALEC icon
Alector
ALEC
+$3.01M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$3M
4
KALV
KalVista Pharmaceuticals
KALV
+$2.61M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.49M

Top Sells

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$10.6M
2
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$10.4M
3
LMNX
Luminex Corp
LMNX
+$5.12M
4
PRQR icon
ProQR Therapeutics
PRQR
+$4.81M
5
TVRD
Tvardi Therapeutics
TVRD
+$4.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAS
51
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$1.88M 0.5%
603,042
– –
LITS
52
Lite Strategy Inc
LITS
$31.6M
$1.77M 0.47%
32,050
– –
BWAY
53
Brainsway
BWAY
$628M
$1.61M 0.43%
400,000
– –
STRO icon
54
Sutro Biopharma
STRO
$400M
$1.61M 0.43%
8,500
– –
REUN
55
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$1.56M 0.42%
+68,180
New +$1.72M
IFRX icon
56
InflaRx
IFRX
$253M
$1.55M 0.41%
600,000
– –
SNDX icon
57
Syndax Pharmaceuticals
SNDX
$1.76B
$1.54M 0.41%
80,702
-67,000
-45% -$1.12M
LONA
58
LeonaBio Inc
LONA
$73.4M
$1.51M 0.4%
16,098
– –
NGM
59
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.38M 0.37%
65,485
+34,983
+115% +$770K
MRSN
60
DELISTED
Mersana Therapeutics
MRSN
$1.32M 0.35%
5,611
+480
+9% +$140K
ASLN
61
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.3M 0.35%
18,313
+1,375
+8% +$156K
BOLT icon
62
Bolt Biotherapeutics
BOLT
$7.44M
$1.26M 0.34%
5,000
– –
NXTC icon
63
NextCure
NXTC
$22.7M
$1.24M 0.33%
15,291
– –
CGEN icon
64
Compugen
CGEN
$218M
$1.2M 0.32%
201,502
– –
ALPN
65
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.19M 0.32%
111,501
-1,801
-2% -$16.6K
HARP
66
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$831K 0.22%
10,516
– –
LVTX
67
DELISTED
LAVA Therapeutics
LVTX
$825K 0.22%
139,332
+3,700
+3% +$26.6K
MASI
68
DELISTED
Masimo
MASI
$812K 0.22%
3,000
– –
INFI
69
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$808K 0.21%
236,160
-223,100
-49% -$688K
LRMR icon
70
Larimar Therapeutics
LRMR
$436M
$744K 0.2%
64,487
-12,500
-16% -$150K
GNFT
71
DELISTED
Genfit
GNFT
$698K 0.19%
188,549
– –
INGN icon
72
Inogen
INGN
$176M
$646K 0.17%
15,000
– –
SRGA
73
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$632K 0.17%
19,324
– –
PHVS icon
74
Pharvaris
PHVS
$2.41B
$622K 0.17%
+35,074
New +$600K
MDGL icon
75
Madrigal Pharmaceuticals
MDGL
$11.8B
$447K 0.12%
5,600
– –
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, DAFNA Capital Management held 91 positions worth $377M, down 21% from $478M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management withdrew a net $18.7M in Q3 2021, closing 11 positions and reducing 15 holdings. Its most notable exit was Theravance Biopharma, an estimated $10.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Cytokinetics worth $6.25M.

  • DAFNA Capital Management's largest Q3 2021 buy was Cytokinetics: 175,000 shares worth $6.25M.
  • DAFNA Capital Management added most to IDEAYA Biosciences in Q3 2021, an estimated $3M increase.
  • DAFNA Capital Management's biggest Q3 2021 reduction was ProQR Therapeutics, cutting an estimated $4.81M.
  • DAFNA Capital Management fully exited Theravance Biopharma in Q3 2021, selling an estimated $10.6M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $377M portfolio in Q3 2021.
  • DAFNA Capital Management opened 7 new positions and closed 11 in Q3 2021.
  • DAFNA Capital Management's portfolio value fell 21% quarter-over-quarter to $377M.

Based on DAFNA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.